{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:30:59Z","timestamp":1761561059296},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,5,25]],"date-time":"2006-05-25T00:00:00Z","timestamp":1148515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p><jats:bold>Abstract:\n\t\t\t\t\tAims: <\/jats:bold> To determine the clinical phenotype and outcome of patients with definite type 1 autoimmune hepatitis, who lack human leukocyte antigen (HLA) DR3 and DR4, and to assess the importance of HLA DR7 and DR13.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> Two hundred and seven adult patients were typed for DR3, DR4, DR7, and DR13 by DNA\u2010based techniques. One hundred and two blood donors constituted a normal population.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Twenty\u2010six patients lacked DR3 and DR4 (13%). Treatment failure occurred more commonly in these individuals than in the 68 patients with DR4 (20% vs. 3%, <jats:italic>P<\/jats:italic>=0.03), and relapse after drug withdrawal was less frequent than in the 84 patients with DR3 (55% vs. 87%, <jats:italic>P<\/jats:italic>=0.03). HLA DR13 occurred more often than in those with DR3 (54% vs. 15%, <jats:italic>P<\/jats:italic>=0.0002) or DR4 (54% vs. 12%, <jats:italic>P<\/jats:italic>=0.00005), and it was more frequent than in normal adults (54% vs. 22%, <jats:italic>P<\/jats:italic>=0.003), including those without DR3 or DR4 (54% vs. 27%, <jats:italic>P<\/jats:italic>=0.03). HLA DR7 was not associated with susceptibility or outcome.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> White North American patients who lack DR3 and DR4 respond differently to corticosteroid treatment than patients with classical HLA phenotypes. HLA DR13 is common in these adult patients, and it may affect treatment outcome.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2006.01249.x","type":"journal-article","created":{"date-parts":[[2006,5,25]],"date-time":"2006-05-25T09:05:56Z","timestamp":1148547956000},"page":"552-558","source":"Crossref","is-referenced-by-count":34,"title":["Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4"],"prefix":"10.1111","volume":"26","author":[{"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herschel A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Breanndan","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,5,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0528.2002.017401.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020166605016"},{"key":"e_1_2_5_4_2","first-page":"701","article-title":"Susceptibility to autoimmune chronic active hepatitis","volume":"13","author":"Donaldson P T","year":"1991","journal-title":"human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90157-8"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250211"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190311"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9178696"},{"key":"e_1_2_5_9_2","first-page":"225","article-title":"Molecular mimicry and autoimmune liver disease","volume":"21","author":"Bogdanos D P","year":"2001","journal-title":"virtuous intentions, malign consequences"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00023-5"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00018-1"},{"key":"e_1_2_5_12_2","first-page":"2197","article-title":"Genetic distinctions between types 1 and 2 autoimmune hepatitis","volume":"92","author":"Czaja A J","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01229.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i12.1862"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(94)90008-6"},{"key":"e_1_2_5_16_2","first-page":"165","article-title":"Analysis of HLA haplotypes in autoimmune hepatitis type 1","volume":"62","author":"Goldberg A C","year":"2001","journal-title":"identifying the major susceptibility locus"},{"key":"e_1_2_5_17_2","first-page":"1374","article-title":"Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina","volume":"30","author":"Pando M","year":"1999","journal-title":"evidence for differential genetic predisposition"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00182-4"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.24562"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34944"},{"key":"e_1_2_5_21_2","first-page":"929","article-title":"International Autoimmune Hepatitis Group report","volume":"31","author":"Alvarez F","year":"1999","journal-title":"review of criteria for diagnosis of autoimmune hepatitis"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2423(05)40004-9"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)91081-R"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-35706"},{"key":"e_1_2_5_25_2","first-page":"876","article-title":"Prednisone for chronic active liver disease","volume":"16","author":"Summerskill W H J","year":"1975","journal-title":"dose titration, standard dose, and combination with azathioprine compared"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00028-4"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(95)00071-B"},{"key":"e_1_2_5_28_2","first-page":"826","article-title":"The HLA dictionary 2001","volume":"62","author":"Schreuder G M","year":"2001","journal-title":"a summary of HLA-A, -B, -C, -DRB1\/3\/4\/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and\u2013DQ antigens"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2006.01249.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2006.01249.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T08:59:22Z","timestamp":1697101162000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2006.01249.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,25]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.1478-3231.2006.01249.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2006.01249.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,25]]}}}